PharmaVitae explores Boehringer Ingelheim’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include regular earnings coverage and provide timely updates to company product forecasts.
PharmaVitae explores Biogen’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
PharmaVitae explores Amgen’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
PharmaVitae explores United Therapeutics’ prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.
PharmaVitae explores Seattle Genetics’ prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.
PharmaVitae explores Ionis Pharmaceuticals’ prescription pharmaceutical performance and outlook over 2019–29.
PharmaVitae explores Alexion’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.
PharmaVitae explores Regeneron’s prescription pharmaceutical performance and outlook over 2019–29.
PharmaVitae explores Kyowa Kirin’s prescription pharmaceutical performance and outlook over 2019–29.
PharmaVitae explores Ono Pharmaceutical’s prescription pharmaceutical performance and outlook over 2019–29.
Between 2011 and 2015, Big Pharma – a peer set of approximately 16 firms across the world with large R&D and sales organizations, and sales valued at $10bn or more – signed over 1,100 drug-focused deals, growing at a compound annual growth rate of 10%.
Low-cost and skilled workforces in China and India have positioned both countries as increasingly important manufacturing hubs for pharmaceutical companies, as they seek to contain costs while retaining quality outsourcing partners.
Despite the apparent inevitability of the contract manufacturing organization (CMO) sector’s growth in China and India, a recent wave of scandals has put significant dents in the reputations of both countries as locations for foreign firms to manufacture drugs. Rising costs have also caused some firms to question whether using one of the region’s many CMOs is worth the risk.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!